ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B
To use anti-CD38 antibody-attenuated interferon alpha-2b fusion constructs to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, and to induce apoptosis in such cells, where the inhibition of proliferation and induction of apoptosis in cancerous cells m...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TAURA TETSUYA ANTHONY GERALD DOYLE COLETTE BEHRENS DAVID S WILSON JR MATTHEW POLLARD YAMAGISHI TETSUO ADAM CLARKE SARAH L POGUE |
| description | To use anti-CD38 antibody-attenuated interferon alpha-2b fusion constructs to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, and to induce apoptosis in such cells, where the inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.SOLUTION: The invention provides antibodies that specifically bind to CD38, and constructs comprising the antibodies fused with attenuated interferon alpha-2B proteins.SELECTED DRAWING: Figure 1
【課題】抗CD38抗体-弱毒化インターフェロンアルファ-2b融合構築物を使用して、CD38と、IFN-アルファ2bの受容体との両方を発現するがん性細胞において増殖を阻害し、そのような細胞におけるアポトーシスを誘導することができる。がん細胞中での増殖の阻害及びアポトーシスの誘導は、原因となるがんの処置のための基礎として役立ち得る。【解決手段】CD38に特異的に結合する抗体、並びに弱毒化インターフェロンアルファ-2Bタンパク質に融合したその前記抗体を含む構築物が提供される。【選択図】図１ |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2020054398A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2020054398A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2020054398A3</originalsourceid><addsrcrecordid>eNrjZHBx9Avx1HV2MbZQALGc_F08XYOBTBcFt9BgT3-_YIVwzxAPBceQEFe_UMcQVxcFT78Q1yA31yB_PwVHnwAPR10jJx4G1rTEnOJUXijNzaDk5hri7KGbWpAfn1pckJicmpdaEu8VYGRgZGBgamJsaeFoTJQiAH0kK9Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B</title><source>esp@cenet</source><creator>TAURA TETSUYA ; ANTHONY GERALD DOYLE ; COLETTE BEHRENS ; DAVID S WILSON JR ; MATTHEW POLLARD ; YAMAGISHI TETSUO ; ADAM CLARKE ; SARAH L POGUE</creator><creatorcontrib>TAURA TETSUYA ; ANTHONY GERALD DOYLE ; COLETTE BEHRENS ; DAVID S WILSON JR ; MATTHEW POLLARD ; YAMAGISHI TETSUO ; ADAM CLARKE ; SARAH L POGUE</creatorcontrib><description>To use anti-CD38 antibody-attenuated interferon alpha-2b fusion constructs to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, and to induce apoptosis in such cells, where the inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.SOLUTION: The invention provides antibodies that specifically bind to CD38, and constructs comprising the antibodies fused with attenuated interferon alpha-2B proteins.SELECTED DRAWING: Figure 1
【課題】抗CD38抗体-弱毒化インターフェロンアルファ-2b融合構築物を使用して、CD38と、IFN-アルファ2bの受容体との両方を発現するがん性細胞において増殖を阻害し、そのような細胞におけるアポトーシスを誘導することができる。がん細胞中での増殖の阻害及びアポトーシスの誘導は、原因となるがんの処置のための基礎として役立ち得る。【解決手段】CD38に特異的に結合する抗体、並びに弱毒化インターフェロンアルファ-2Bタンパク質に融合したその前記抗体を含む構築物が提供される。【選択図】図１</description><language>eng ; jpn</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200409&DB=EPODOC&CC=JP&NR=2020054398A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200409&DB=EPODOC&CC=JP&NR=2020054398A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TAURA TETSUYA</creatorcontrib><creatorcontrib>ANTHONY GERALD DOYLE</creatorcontrib><creatorcontrib>COLETTE BEHRENS</creatorcontrib><creatorcontrib>DAVID S WILSON JR</creatorcontrib><creatorcontrib>MATTHEW POLLARD</creatorcontrib><creatorcontrib>YAMAGISHI TETSUO</creatorcontrib><creatorcontrib>ADAM CLARKE</creatorcontrib><creatorcontrib>SARAH L POGUE</creatorcontrib><title>ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B</title><description>To use anti-CD38 antibody-attenuated interferon alpha-2b fusion constructs to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, and to induce apoptosis in such cells, where the inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.SOLUTION: The invention provides antibodies that specifically bind to CD38, and constructs comprising the antibodies fused with attenuated interferon alpha-2B proteins.SELECTED DRAWING: Figure 1
【課題】抗CD38抗体-弱毒化インターフェロンアルファ-2b融合構築物を使用して、CD38と、IFN-アルファ2bの受容体との両方を発現するがん性細胞において増殖を阻害し、そのような細胞におけるアポトーシスを誘導することができる。がん細胞中での増殖の阻害及びアポトーシスの誘導は、原因となるがんの処置のための基礎として役立ち得る。【解決手段】CD38に特異的に結合する抗体、並びに弱毒化インターフェロンアルファ-2Bタンパク質に融合したその前記抗体を含む構築物が提供される。【選択図】図１</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHBx9Avx1HV2MbZQALGc_F08XYOBTBcFt9BgT3-_YIVwzxAPBceQEFe_UMcQVxcFT78Q1yA31yB_PwVHnwAPR10jJx4G1rTEnOJUXijNzaDk5hri7KGbWpAfn1pckJicmpdaEu8VYGRgZGBgamJsaeFoTJQiAH0kK9Y</recordid><startdate>20200409</startdate><enddate>20200409</enddate><creator>TAURA TETSUYA</creator><creator>ANTHONY GERALD DOYLE</creator><creator>COLETTE BEHRENS</creator><creator>DAVID S WILSON JR</creator><creator>MATTHEW POLLARD</creator><creator>YAMAGISHI TETSUO</creator><creator>ADAM CLARKE</creator><creator>SARAH L POGUE</creator><scope>EVB</scope></search><sort><creationdate>20200409</creationdate><title>ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B</title><author>TAURA TETSUYA ; ANTHONY GERALD DOYLE ; COLETTE BEHRENS ; DAVID S WILSON JR ; MATTHEW POLLARD ; YAMAGISHI TETSUO ; ADAM CLARKE ; SARAH L POGUE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2020054398A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>TAURA TETSUYA</creatorcontrib><creatorcontrib>ANTHONY GERALD DOYLE</creatorcontrib><creatorcontrib>COLETTE BEHRENS</creatorcontrib><creatorcontrib>DAVID S WILSON JR</creatorcontrib><creatorcontrib>MATTHEW POLLARD</creatorcontrib><creatorcontrib>YAMAGISHI TETSUO</creatorcontrib><creatorcontrib>ADAM CLARKE</creatorcontrib><creatorcontrib>SARAH L POGUE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TAURA TETSUYA</au><au>ANTHONY GERALD DOYLE</au><au>COLETTE BEHRENS</au><au>DAVID S WILSON JR</au><au>MATTHEW POLLARD</au><au>YAMAGISHI TETSUO</au><au>ADAM CLARKE</au><au>SARAH L POGUE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B</title><date>2020-04-09</date><risdate>2020</risdate><abstract>To use anti-CD38 antibody-attenuated interferon alpha-2b fusion constructs to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, and to induce apoptosis in such cells, where the inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.SOLUTION: The invention provides antibodies that specifically bind to CD38, and constructs comprising the antibodies fused with attenuated interferon alpha-2B proteins.SELECTED DRAWING: Figure 1
【課題】抗CD38抗体-弱毒化インターフェロンアルファ-2b融合構築物を使用して、CD38と、IFN-アルファ2bの受容体との両方を発現するがん性細胞において増殖を阻害し、そのような細胞におけるアポトーシスを誘導することができる。がん細胞中での増殖の阻害及びアポトーシスの誘導は、原因となるがんの処置のための基礎として役立ち得る。【解決手段】CD38に特異的に結合する抗体、並びに弱毒化インターフェロンアルファ-2Bタンパク質に融合したその前記抗体を含む構築物が提供される。【選択図】図１</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2020054398A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | ANTI-CD38 ANTIBODIES AND FUSIONS WITH ATTENUATED INTERFERON ALPHA-2B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TAURA%20TETSUYA&rft.date=2020-04-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2020054398A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |